Prostate cancer that returns after radiation therapy—known as radio-recurrent prostate cancer—presents a complex clinical challenge, but a comprehensive review from Yale School of Medicine researchers offers clarity on the available management strategies. The review examines the full spectrum of treatment options, from androgen deprivation therapy (ADT) to salvage surgical procedures and re-irradiation techniques, while emphasizing that patient selection is critical for successful outcomes. Key findings show that local recurrences can be effectively treated with salvage therapies including radical prostatectomy, brachytherapy, cryotherapy, and high-intensity focused ultrasound, with success rates ranging from 30% to slightly over 50% depending on disease progression. The review highlights that while significant functional side effects exist with some salvage treatments, newer technologies and careful patient selection based on PSA levels, Gleason scores, and PSA doubling time can dramatically improve outcomes.
Prostate cancer is the most commonly diagnosed cancer among men worldwide. The widespread use of prostate-specific antigen (PSA) testing has enabled earlier detection, which has shifted treatment approaches toward more personalized and patient-focused strategies. Many men choose primary radiation therapy (RT) as their initial treatment because it offers low morbidity and preserves health-related quality of life—important considerations for many patients.
However, a significant number of men who undergo radiation therapy will experience a rise in PSA levels afterward, indicating possible recurrence. Data from the phase III RTOG 0521 trial, which followed patients for 10 years, showed that approximately 40% of high-risk prostate cancer patients experience a PSA rise after radiation. It's important to understand that not every PSA rise means treatment failure—PSA elevation can occur from normal testosterone recovery after radiation, which is often expected.
Another major study, RTOG 0815, investigated patients receiving different durations of ADT after radiation therapy and found a biochemical recurrence (BCR) rate of 25% over 10 years. This means that one in four men who undergo radiation therapy will eventually show signs of recurrence, making this a pressing clinical challenge.
The recurrence of prostate cancer after radiation requires a nuanced management strategy that considers disease stage and aggressiveness, patient health status, and prior treatment modalities. Currently, there is no standardized approach to evaluating and treating radio-recurrent prostate cancer, which is why this comprehensive review is so valuable for patients and their healthcare providers.
Diagnosing locally recurrent prostate cancer after primary radiation therapy presents unique challenges. The tissues that have been exposed to radiation undergo biochemical alterations that can make interpretation of test results more difficult. The diagnostic process typically involves a combination of imaging studies and biopsy procedures.
Traditional imaging evaluation has included computed tomography (CT) scans of the abdomen and pelvis, prostate magnetic resonance imaging (MRI), and bone scans. These tests focus on detecting metastatic disease and evaluating the local extent of any tumor recurrence. However, newer imaging technologies are rapidly changing how doctors approach this diagnosis.
Positron emission tomography (PET) CT scans have become increasingly important in evaluating radio-recurrent prostate cancer. A study by Fanti and colleagues explored the effectiveness of PET CT scans using 11C-choline for assessing lymph node metastases and other distant lesions. These scans demonstrated a sensitivity and specificity of 87% each for detecting overall relapse, with a sensitivity of 61% and specificity of 97% specifically for local relapse.
Gallium (Ga)-68 prostate-specific membrane antigen (PSMA) PET CT has been increasingly utilized because of its ability to better identify locally radio-recurrent prostate cancer while ruling out distant metastases. In a study of 50 patients, Pfister and colleagues found that Ga-68 PSMA PET CT scans had sensitivity and positive predictive value (PPV) of 100%, with accuracy of 100% (92.89–100%) for detecting local recurrence.
Another study by Rasing evaluated 41 patients who were considering focal salvage therapy and found that combined MRI and PSMA PET led to a high PPV of 97.6% relative to prostate biopsy. A recent study also pointed out the usefulness of MRI and PSMA PET CT in staging (pT3 detection) and assessing lymph node metastasis in 113 patients who underwent salvage radical prostatectomy (SRP) for recurrent cancer after radiation therapy.
These advanced imaging techniques are transforming how doctors detect recurrent prostate cancer, potentially allowing some patients to avoid unnecessary biopsies while ensuring that distant metastases are not missed.
Prostate biopsy is recommended before initiating any salvage therapy. Interestingly, Crook and colleagues found that 30% of positive biopsies taken within 2 years post-radiation eventually converted to negative biopsies within 24–30 months. This suggests that some early positive findings may resolve on their own.
In contrast, Shipley and colleagues noted the prognostic value of biopsy timing. Positive biopsies taken 2 years post-radiation were indicative of lower 5-year disease-free survival (DFS) rates compared to negative and indeterminate biopsies in pooled institutional analyses. In an evaluation of 99 patients who were biopsied due to rising PSA after radiation, Zagars and colleagues found that 86 had cancer recurrence, of which 72% were local alone.
Based on these findings, prostate biopsy is recommended for patients with rising serum PSA levels 1–2 years after radiation therapy. However, the study by Rasing and colleagues suggests that prostate biopsies may be avoided in patients with rising PSA values with a median time of 7 years post-radiation, thanks to the robust PPV of PSMA and MRI imaging.
Takeda and colleagues mapped the areas of the prostate most likely to show recurrence after prior radiation. They found that recurrence most commonly occurs at the distal apex, seminal vesicles (which are not always included in a biopsy), and the periurethral region. Recently, MRI-guided targeted biopsies have been shown to help better determine which patients can forgo prostate biopsy if salvage focal ablation is planned.
Determining ideal candidates for salvage therapy is pivotal, yet there is no consensus on patient selection. Various clinical parameters can help patients understand the likelihood of success of local salvage therapy.
A review by Touma and colleagues found that patients with a PSA less than 10 ng/mL, clinical stage T1c or T2, and a Gleason score (GS) less than 8 showed improved recurrence-free survival (RFS) rates after SRP. Additionally, data has demonstrated an association between shorter PSA-doubling time (DT) and increased risk of distant metastases or cancer-related deaths.
More recently, Mandel and colleagues evaluated selection criteria for SRP using the European Association of Urology (EAU) guideline. This included patients with:
Patients meeting these criteria exhibited a 5-year RFS rate of 73.9% with significantly reduced rates of lymph node and distant metastases. This means that carefully selected patients can achieve excellent outcomes with salvage therapy.
ADT remains a cornerstone treatment option for radio-recurrent prostate cancer, particularly for patients with regional or distant relapse. ADT works by targeting androgen signaling, effectively suppressing tumor growth. However, its therapeutic impact, especially as a monotherapy, is uncertain.
A study from the CaPSURE database evaluated 2,096 patients with biochemical recurrence post-radiation or surgery and demonstrated no substantial benefit for immediate ADT compared to deferred introduction. With a median follow-up of 54 months, the hazard ratio (HR) for mortality was 0.91 (95% confidence interval: 0.52–1.60). The estimated 5-year overall survival (OS) was 85.7% for immediate ADT compared to 87.7% for deferred ADT, and the 10-year OS was also similar at 69.8% and 69.3%.
However, a retrospective assessment of 5,804 men with biochemical recurrence post-primary therapy showed that salvage ADT correlated with reduced overall mortality or cancer-specific mortality in the post-radiation group, with HR values of 0.62 and 0.65, specifically for patients with a PSA doubling time of less than 9 months.
Recent data from randomized prospective trials provides important insights. The TOAD study, involving 293 men with biochemical recurrence after prior radiation or surgery, highlighted the potential benefits of ADT for locally recurrent prostate cancer. Notably, 52% of the cohort began ADT within 2 years. Among patients presenting with high-risk features such as short PSA doubling time, the median delay to initiating ADT was 12.3 months.
The results favored immediate ADT, showing:
Between groups, immediate ADT was preferred with an HR of 0.30 (P<0.001) when examining the onset of castration resistance from treatment commencement. This means that starting ADT earlier significantly delayed the development of castration-resistant disease.
A study analyzing 432 men with T1–3N0M0 prostate cancer and PSA failure after intensity-modulated radiation therapy (IMRT) found that the 7-year cancer-specific survival (CSS) was 61% for individuals with a PSA doubling time of less than 6 months, contrasting with 85% for those exceeding this cutoff (P=0.0001). Thus, a PSA doubling time cutoff of 6 months has emerged as an important determinant for commencing ADT in prostate cancer patients with biochemical recurrence.
It is important to note that patient selection is critical when deciding to use salvage ADT. Trials such as ELAAT and TOAD investigated the optimal timing of ADT initiation in post-radiation PSA rise. Combined pooled analysis demonstrated no difference in all-cause mortality but improvement in time to local progression with immediate ADT. The ELAAT trial involved significantly older men with a higher comorbid all-mortality risk, while TOAD incorporated higher-risk patients that may have benefited from immediate ADT (30% of patients with a relapse-free interval of less than 3 years).
When deciding to use salvage ADT, it is important to balance the benefit of initiating androgen deprivation with the competing risks of age and comorbidities, particularly in those with a high risk of all-cause mortality.
SRP is an effective management option for men with localized radio-recurrent prostate cancer, offering a potentially curative approach. However, current insights on SRP are entirely based on retrospective studies, meaning there are no large randomized controlled trials to guide decision-making.
In a retrospective multi-institutional cohort analysis conducted by Chade and colleagues, a total of 404 patients treated with SRP were examined. The median follow-up period was 4.4 years, the median age was 65 years, and the median PSA was 4.5 ng/mL. Crucially, a decade after undergoing SRP, the probabilities of:
Patients with a pre-SRP PSA of 4 or less and a pre-SRP prostate biopsy Gleason grade of 7 or less had survival rates of 64% at 5 years and 51% at 10 years. This demonstrates that patients with more favorable characteristics at the time of surgery achieve substantially better outcomes.
In another multicenter study of 414 patients treated with SRP, the 5-year biochemical recurrence-free survival, cancer-specific survival, and disease-specific survival rates were 56.7%, 97.7%, and 92.1%, respectively. Pathologic stage of pT3 or higher and Gleason score of 8 or higher were the most important factors associated with biochemical recurrence.
A recent multicenter retrospective study showed better metastasis-free survival, PSA-free survival, and overall survival in the favorable prognosis group according to EAU criteria compared to other groups. In a systematic review, SRP was associated with 5- and 10-year biochemical recurrence-free survival rates of 47% to 82% and 28% to 53%, respectively. Pre-SRP PSA level and prostate biopsy International Society of Urological Pathology (ISUP) grade were strong predictors of organ-confined disease, progression, and cancer-specific survival.
Regarding morbidity, compared to primary open radical prostatectomy, SRP has significantly higher risk of complications:
Functional outcomes are also unfavorable compared with primary open radical prostatectomy, with higher rates of urinary incontinence (21–90%) and erectile dysfunction (ED) in nearly all patients.
Gontero and colleagues reported on the feasibility of robotic SRP in a multicenter study of 395 prostate cancer patients who recurred after non-surgical treatments. While the robotic SRP resulted in reduced blood loss and shorter hospital stay, the overall complication rate was comparable between the open and robotic approach. Interestingly, the post-operative continence rate was higher in the robotic SRP group compared to open SRP (64.61% versus 47.15%).
In summary, SRP can achieve good oncological outcomes in patients with locally recurrent prostate cancer after radiation, with most favorable results in patients with:
However, significant functional side effects including high rates of urinary incontinence and sexual dysfunction, as well as increased complications such as rectal injury, must be weighed against the oncologic benefits.
Salvage brachytherapy (BT) involves placing radioactive seeds or sources directly into the prostate to deliver high doses of radiation to the recurrent tumor while sparing surrounding tissues. There are two main types: low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy.
LDR brachytherapy is an acceptable salvage procedure for patients who recur after primary external beam radiation therapy (EBRT). Smith and colleagues studied 108 patients from two institutions. With a median follow-up of 6.3 years, the 5- and 10-year biochemical recurrence-free rates were 63.1% and 52.0%, respectively. In multivariate analysis, higher grade group and elevated PSA level at diagnosis were associated with worse outcomes. Grade 3 toxicity occurred in 16.7% of patients, with genitourinary (GU) events in 15.7% and gastrointestinal (GI) events in 2.8%.
The NRG RTOG 0526 phase 2 trial led by Crook investigated transperineal ultrasound-guided LDR brachytherapy for patients with local recurrence post-EBRT. One hundred patients were registered from 20 institutions, primarily with low-to-intermediate-risk profiles including PSA less than 10 ng/mL prior to salvage brachytherapy. With a median follow-up of 54 months, 92 patients underwent the salvage brachytherapy with ADT used in 16% of the cohort. Late grade 3 GU and GI toxicities were 13% and 1%, respectively, with no grade 4 or 5 events.
In an update of this study, Crook and colleagues revealed that with a median follow-up extending to 6.9 years:
Partial gland LDR brachytherapy aims to treat only the region of the prostate where cancer has recurred. Theoretically, this method spares the surrounding tissues and leads to fewer side effects. Kunogi and colleagues evaluated 12 patients who underwent focal partial salvage re-implantation after experiencing local recurrence following initial LDR brachytherapy using iodine-125 seeds. The study showed a promising 4-year biochemical recurrence-free survival rate of 78%. Remarkably, this study reported no grade 3 GU or GI toxicities, nor any deaths post-salvage re-implantation.
Another retrospective study on 20 patients who underwent focal salvage LDR brachytherapy following primary radiation therapy reported a 3-year biochemical recurrence-free survival rate of 60% after a median follow-up of 36 months. Side effects were minimal, with only one patient experiencing a grade 3 GU toxicity, specifically urethral stricture. No complications greater than grade 4 were noted. An encouraging aspect of this study was the potency preservation in all five patients who were potent prior to undergoing the salvage treatment.
Investigators from Scripps Clinic and the University of California-San Francisco (UCSF) reported on 52 patients treated with salvage HDR brachytherapy after definitive radiation therapy for prostate cancer. With a median follow-up of nearly 60 months, the 5-year biochemical recurrence-free survival rate was 51%. The incidence of grade 3 GU toxicity was only 2%, with late grade 2 GI toxicity occurring in 4% of patients.
Wu and colleagues studied 129 patients who had salvage whole-gland HDR brachytherapy after initial definitive radiation therapy from 1998 to 2016 at UCSF. Most patients initially presented with stage T1–2 (73%) and Gleason score 6–7 (82%), with a median disease-free interval (DFI) of 56 months. The median PSA at the time of salvage therapy was 4.95 ng/mL. Notably, with a median follow-up of 68 months:
Wojcieszek and colleagues reported on 83 patients treated with salvage HDR brachytherapy. With a median follow-up of 41 months, the 3-year biochemical recurrence-free survival was 76% and 5-year was 67%. Overall survival at 3 years was 93% and at 5 years was 86%. Grade 3 GU toxicity occurred in 13% of patients, with no grade 2 or 3 GI toxicities reported.
Henríquez López and colleagues conducted a multicenter retrospective study of 44 patients treated with LDR and 75 patients treated with HDR salvage brachytherapy. With a median follow-up of 52 months, the overall 5-year biochemical recurrence-free survival was 71%. The 5-year cancer-specific survival was 96.5% for LDR and 93% for HDR. Grade 3 or more toxicity occurred in 23.5% of patients.
Focal HDR brachytherapy has also been explored. Murgic and colleagues conducted a prospective study of 15 patients with a median follow-up of 36 months, showing a 3-year biochemical recurrence-free survival of 61% with only one grade 3 GU toxicity. Maenhout and colleagues reported on 17 patients with a median follow-up of only 10 months, with only one patient showing biochemical recurrence and one grade 3 urethral stricture at 2 years. Van Son and colleagues studied 50 patients with a median follow-up of 31 months, reporting a 2.5-year biochemical recurrence-free survival of 51%, metastasis-free survival of 75%, and overall survival of 98%. Grade 3 GU toxicity occurred in only 2% of patients, with no grade 3 GI toxicity.
Beyond surgery and brachytherapy, several other local treatments have been applied as salvage therapy for radio-recurrent prostate cancer with promising results. These include:
These modalities offer additional options for patients who may not be good candidates for surgery or re-irradiation, though the evidence base is still evolving. The review notes that exploring new avenues for improved outcomes and personalized treatment strategies, as well as clinical trials investigating novel therapeutic agents and combination therapies, remain imperative for these men.
For patients facing a prostate cancer recurrence after radiation therapy, this comprehensive review provides several important takeaways. First, a rising PSA after radiation does not automatically mean treatment failure. Up to 40% of patients may experience PSA elevation, and some of these rises are due to normal testosterone recovery rather than cancer recurrence. Patients should work with their urologists to determine whether a PSA rise warrants further investigation.
Second, modern imaging techniques, particularly PSMA PET CT scans, have dramatically improved the ability to detect local recurrence and rule out distant metastases. In some cases, these advanced scans may even eliminate the need for biopsy, especially in patients who are more than 7 years post-radiation.
Third, multiple effective treatment options exist for radio-recurrent prostate cancer. The choice of treatment depends on several factors:
For patients with localized recurrence, salvage radical prostatectomy offers the potential for cure, with 5-year biochemical recurrence-free survival rates of 47–82% in well-selected patients. However, this must be balanced against significant risks of urinary incontinence (21–90%) and erectile dysfunction in nearly all patients.
Salvage brachytherapy offers an alternative with more favorable side effect profiles. Modern series show 5-year biochemical recurrence-free survival rates of 51–71% for HDR brachytherapy and 52–63% for LDR brachytherapy, with lower rates of severe toxicity. Focal approaches that treat only the recurrent area may offer even better side effect profiles while maintaining reasonable cancer control.
For patients with more aggressive or widespread disease, ADT remains an important treatment option. The TOAD trial demonstrated that immediate ADT improved 5-year overall survival from 86.4% to 91.2% compared to deferred treatment, and significantly delayed the development of castration-resistant disease (HR 0.30, P<0.001).
It is important to acknowledge the limitations of the evidence presented in this review. The authors note that current insights on salvage radical prostatectomy are entirely based on retrospective studies, which are subject to selection bias and confounding factors. There are no large randomized controlled trials comparing different salvage treatment modalities head-to-head.
Additionally, the efficacy rates for various salvage treatments range between 30% to slightly over 50%, largely dependent on the progression of disease during the treatment decision phase. This wide range reflects the heterogeneity of patients and the lack of standardized selection criteria.
The review also acknowledges that declaring recurrence following radiation without prostate biopsy must be scrutinized and should be assessed via carefully designed clinical trials. While advanced imaging shows promise, further studies on the utility of these imaging modalities are necessary to improve the detection of locally recurrent prostate cancer after primary radiation therapy.
Finally, establishing a reasonable threshold for PSA doubling time for ADT initiation requires additional studies. The 6-month cutoff that has emerged from existing data may not be optimal for all patient populations.
Based on this comprehensive review, patients facing radio-recurrent prostate cancer should consider the following recommendations:
Ultimately, the management of radio-recurrent prostate cancer requires a personalized approach that considers the individual patient's cancer characteristics, overall health, and personal values. This comprehensive review provides the framework for informed decision-making, but each patient's situation is unique and deserves careful discussion with their healthcare team.
A rising PSA after radiation does not always mean the cancer has returned. Up to 40% of high-risk patients may have a PSA rise, sometimes due to normal testosterone recovery. Your doctor will evaluate your PSA pattern, imaging, and possibly a biopsy to determine if recurrence is present.
Diagnosis typically involves imaging such as PSMA PET CT or MRI, and a prostate biopsy. In a study of 50 patients, PSMA PET CT had 100% sensitivity and accuracy for detecting local recurrence. Biopsy is generally recommended, but may be avoided in some patients more than 7 years after radiation if imaging is strongly positive.
Options include salvage radical prostatectomy, salvage brachytherapy (LDR or HDR), cryotherapy, HIFU, and androgen deprivation therapy (ADT). The choice depends on whether the cancer is localized or spread, your health, and cancer aggressiveness. Success rates vary, with 5-year biochemical recurrence-free survival ranging from about 47% to 82% for surgery and 51% to 71% for brachytherapy.
Favorable criteria include PSA less than 10 ng/mL, Gleason score less than 8, clinical stage T1c or T2, and PSA doubling time greater than 6 months. In a study using EAU criteria, patients meeting these had a 5-year recurrence-free survival of 73.9%. Your doctor will assess your specific situation.
Compared to primary surgery, salvage prostatectomy has higher risks: anastomotic stricture (48% vs 5.8%), urinary retention (25.3% vs 3.5%), rectal injury (9.2% vs 0.6%), and urinary incontinence (21–90%). Erectile dysfunction occurs in nearly all patients. Robotic surgery may reduce blood loss and hospital stay, with better continence rates in one study.
Salvage brachytherapy places radioactive seeds (LDR) or uses high-dose-rate (HDR) sources to treat the recurrent tumor. In studies, 5-year biochemical recurrence-free survival was 52–63% for LDR and 51–71% for HDR. Grade 3 urinary toxicity occurred in 2–16.7% of patients. Focal approaches may have fewer side effects.
ADT is often used for regional or distant relapse. The TOAD trial showed immediate ADT improved 5-year overall survival (91.2% vs 86.4%) compared to deferred treatment. A PSA doubling time of less than 6 months is an important factor for starting ADT. However, benefits must be weighed against age and comorbidities.
Original Article Title: Management strategies for radio-recurrent prostate cancer- a comprehensive review
DOI: 10.21037/tcr-24-245
Authors: Syed N. Rahman, Hyung Suk Kim, Lindsey T. Webb, Gabriela M. Diaz, Michael S. Leapman, Preston C. Sprenkle, Joseph M. Brito, Joseph Renzulli, Thomas V. Martin, Patrick Kenney, Isaac Yi Kim
Affiliation: Department of Urology, Yale School of Medicine, New Haven, CT, USA; Department of Urology, Dongguk University School of Medicine, Dongguk University Ilsan Medical Center, Goyang-si, Korea
Journal: Translational Cancer Research, Vol 13, No 11, November 2024
Publication Details: Submitted Feb 12, 2024; Accepted for publication Jun 05, 2024; Published online Jul 16, 2024
DOI: 10.21037/tcr-24-245
This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace professional medical advice. Patients should consult with their healthcare providers about their specific situations.
Use collapsible tabs for more detailed information that will help customers make a purchasing decision.
Ex: Shipping and return policies, size guides, and other common questions.